Eli Lilly CEO pushes back on Dario Amodei's ludicrous medical claims

Gary Marcus argues that Anthropic CEO Dario Amodei’s claim that AI could make cancer, Alzheimer’s, heart disease, and mental illness relics within a decade is a reckless overpromise, especially when made around an IPO. Marcus says these conditions are complex and cannot plausibly be cured on that schedule; mental illness in particular is not a problem with a simple technological fix. He compares the claims to Elizabeth Holmes’s Theranos promises, arguing that investors and the public should be wary of sweeping medical predictions made to promote a company.

Researchers and industry figures quoted in the discussion say AI may help drug development, but major obstacles remain. Biological data are sparse, and medicines must still pass manufacturing, regulatory review, and human clinical trials that cannot simply be skipped. One estimate puts the average time from first human testing to approval for recently approved drugs at 14 years, with a median of 10. Eli Lilly CEO Dave Ricks calls rapid cures unlikely, citing how much of biology remains unknown and the need for randomized human evidence; AI, he expects, will bring steady, incremental progress. Even prominent AI optimists reject Amodei’s timeline. Marcus faults major media for not scrutinizing the claims and says their timing and scale warrant investigation, potentially for securities fraud.